TIDMARIX
Arix Bioscience plc
Correction: Results of Annual General Meeting
With correction to Table of Resolutions - Numbers 02 and 03.
LONDON, 03 June 2019: Arix Bioscience plc ("Arix", LSE: ARIX) a global venture
capital company focused on investing and building breakthrough biotech
companies, announces that its Annual General Meeting (the "Meeting") was held
on Monday, 3 June 2019 at 10.30am (BST). At the Meeting, the ordinary and
special resolutions set out in the Notice of the Annual General Meeting dated 2
May 2019 (the "Notice of AGM"), were proposed and voted on by way of a poll.
Full details of the poll results are set out below and will also be available
on the Company's website www.arixbioscience.com.
No RESOLUTION VOTES FOR % VOTES % TOTAL % of VOTES
AGAINST VOTES ISC WITHHELD
VOTED
01 To receive 79,740,015 100.00 0 0.00 79,740,015 58.86% 3,894
the
Directors'
report and
the accounts
for the
Company for
the year
ended 31
December
2018
02 To approve 40,079,954 50.26 39,658,365 49.74 79,738,319 58.86% 5,590
the
Directors'
Remuneration
Policy
03 To approve 23,179,050 32.41 48,338,181 67.59 71,517,231 52.79% 8,226,678
the
Directors'
Remuneration
Report for
the year
ended 31
December
2018
04 To re-elect 75,716,711 94.95 4,025,628 5.05 79,742,339 58.86% 1,570
Jonathan
Peacock as a
Director
05 To re-elect 74,175,937 93.02 5,566,402 6.98 79,742,339 58.86% 1,570
Dr Franz
Humer as a
Director
06 To re-elect 77,691,164 97.43 2,050,547 2.57 79,741,711 58.86% 2,198
Professor
Trevor Jones
as a
Director
07 To re-elect 79,739,711 100.00 2,628 0.00 79,742,339 58.86% 1,570
Giles Kerr
as a
Director
08 To re-elect 79,741,711 100.00 628 0.00 79,742,339 58.86% 1,570
Dr Joseph
Anderson as
a Director
09 To re-elect 79,741,711 100.00 628 0.00 79,742,339 58.86% 1,570
James
Rawlingson
as a
Director
10 To elect Art 76,266,164 95.64 3,476,175 4.36 79,742,339 58.86% 1,570
Pappas as a
Director
11 To elect 79,741,711 100.00 0 0.00 79,741,711 58.86% 2,198
Mark Breuer
as a
Director
12 To 72,224,733 90.57 7,524,156 9.43 79,748,889 58.87% 4,020
re-appoint
PwC LLP as
auditors of
the Company
13 To authorise 78,313,875 98.21 1,426,485 1.79 79,740,360 58.86% 3,549
the Audit &
Risk
Committee of
the Company
to fix the
remuneration
of the
auditors
14 To authorise 73,634,398 92.34 6,105,491 7.66 79,739,889 58.86% 4,020
the
Directors to
allot shares
15 To authorise 70,676,320 88.63 9,063,088 11.37 79,739,408 58.86% 4,501
the
Directors to
disapply
statutory
pre- emption
rights in
respect of
5% of the
Company's
issued
share
capital*
16 To authorise 71,033,320 89.08 8,706,088 10.92 79,739,408 58.86% 4,501
the
Directors to
disapply
statutory
pre- emption
rights in
respect of
an
additional
5% of the
Company's
issued share
capital*
17 To authorise 79,736,396 99.99 5,063 0.01 79,741,459 58.86% 2,450
the Company
to buy back
shares*
18 To authorise 79,739,242 100.00 2,250 0.00 79,741,492 58.86% 2,417
the
Directors to
call a
general
meeting
other than
an annual
general
meeting on
not less
than 14
clear days'
notice*
* Special resolution
In accordance with Listing Rule 9.6.2, copies of resolutions passed at the
Meeting concerning items other than ordinary business will shortly be available
for inspection on the National Storage Mechanism, which can be accessed at
www.hemscott.com/nsm.do
The Board is pleased that all resolutions at the meeting were passed other than
the resolution to approve last year's Directors' Remuneration Report,
Resolution 3. Over the next six months we shall engage with those shareholders
we can identify who did not support this resolution to fully understand their
concerns. Engagement will also take place with the small number of shareholders
who did not support the resolution to approve the new Directors' Remuneration
Policy, which was passed but with a significant minority of votes against.
Since being set up in 2016, the Arix portfolio has grown and developed with 17
investments to date and four IPOs of portfolio companies in the past year.
Multiple clinical milestones are expected over the next 12 months and the
Company looks forward to reporting on continued progress throughout the year.
ENDS
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur
T: +44 (0) 203 922 0891
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in
and building breakthrough biotech companies around cutting edge advances in
life sciences.
We collaborate with exceptional entrepreneurs and provide the capital,
expertise and global networks to help accelerate their ideas into important new
treatments for patients. As a listed company, we are able to bring this
exciting growth phase of our industry to a broader range of investors.
www.arixbioscience.com
END
(END) Dow Jones Newswires
June 04, 2019 06:59 ET (10:59 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024